Combining biomarkers for prognostic modelling of Parkinson’s disease
Output Details
Preprint November 2, 2021
Published July 12, 2022
- APOE (Apolipoprotein E)
- Biomarkers
- Blood
- DNA
- GBA (Glucocerebrosidase)
- Genotyping
- Motor symptoms
- NfL (Neurofilament light)
- Original Research
- Prognostic modeling
- SNPs (Single Nucleotide Polymorphisms)
Meet the Authors
-
-
-
-
-
-
-
Christine Girges
External Collaborator
-
Viorica Chelban
External Collaborator
-
Katherine A Grosset
External Collaborator
-
John Woodside
External Collaborator
-
Manuela Tan
External Collaborator
-
Tong Guo
External Collaborator
-
Michael Lawton
External Collaborator
-
Amanda Heslegrave
External Collaborator
-
Nirosen Vijiaratnam
External Collaborator
-
Ben-Shlomo Yoav
External Collaborator
-
Thomas Foltynie
External Collaborator
-
Henry Houlden
External Collaborator
-
Henrik Zetterberg
External Collaborator
-
Dilan Athauda
External Collaborator
-
Nigel Williams
External Collaborator
-
Donald Grosset
External Collaborator
Related Research
SNP Genotyping and ApoE Genotyping
Protocol outlines DNA extraction from blood, quality control, SNP, and APOE genotyping. Adapted from PRoBaND SNP Genotyping and ApoE Genotyping Protocol by Malek et al. for Parkinson's Disease study.
huw-morris-lab/PDD_GWSS
The manuscript by Real et al. investigates the relationship between LRP1B and APOE loci and the onset of Parkinson’s disease dementia, utilizing specific code for analysis.
Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia
Genetic analysis of 3,964 PD cases revealed APOE-ϵ4 allele and new loci as risk factors for PD dementia progression, implicating amyloid pathway in PDD development and potential for amyloid-targeting therapy.